• About Us
  • Company Background
    • History of helping others
  • Corporate Brochure
  • Message from the GM
• Products
• Patient Support
• Research & Development
• Business Development
  • Partnering with Teva
  • Contact Info
• Our Working Environment
  • Who we are
  • Employer of Choice
    • Community Involvement
• Helpful Links
  • Multiple Sclerosis
  • Parkinson's disease
  • Migraine
  • Government of Canada
    Recall and Safety Alerts
• News and Media

Business Development: Partnering with Teva Canada Innovation

Teva Canada Innovation has a history of partnering with companies to leverage its R&D and commercial capabilities to advance the company’s growth.

From a global perspective, Teva has formed several key partnerships to further research in neurology and continues to seek opportunities to extend the current competencies to other areas in neurology.

As part of the commitment to furthering the treatment of MS, Teva partnered with Active Biotech, a Swedish company with a potential breakthrough oral medication for the treatment of Multiple Sclerosis. The product, laquinimod, is in the final phase of clinical trials.

Teva Canada Innovation and Teva Pharmaceuticals Ltd are seeking in-licensing or collaborative opportunities at any stage of development in the following therapeutic areas:

• Multiple sclerosis and other neurological conditions
• Auto-immune
• Oncology
• Biologics
• Women’s health
• Respiratory

In Canada, Teva Canada Innovation signed an agreement with Endo Pharmaceuticals for the right to commercialize Frova^®, in Canada. Teva Canada Innovation is an excellent choice for a partner as we:

• Are committed to partnering
• Are structured in a manner which enhances communication and results
• Have a proven track record for success
• Are open to various deal structures